TRAVERE THERAPEUTICS INC (TVTX)
Health Care · Rare kidney and metabolic disease therapeutics · NASDAQ
Rare kidney disease specialist with two approved FILSPARI formulations (IgAN, FSGS) and a clinical-stage enzyme therapy poised to become the first disease-modifying treatment for homocystinuria.
What TRAVERE THERAPEUTICS INC does
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and commercializing life-changing therapies for rare kidney and metabolic diseases with significant unmet medical needs. The company has commercialized FILSPARI® (sparsentan), a dual endothelin-angiotensin receptor antagonist approved for IgAN and FSGS, and is advancing pegtibatinase, a novel enzyme replacement therapy for homocystinuria. Travere leverages its specialized commercial organization and rare disease expertise to bring novel treatments to patients with limited existing therapeutic options.
Themes: ["rare kidney diseases","rare metabolic diseases","orphan drugs","IgAN treatment","FSGS treatment","homocystinuria"]
Fundamentals
- Price$58.47 as of 2026-07-09 close
- Market cap$5.4B as of 2026-07-10
- 1-year return+258.1% as of 2026-07-09 close
- Net margin-4.0% as of 2026-07-10
- Gross margin+98.6% as of 2026-07-10
- ROE-26.8% as of 2026-07-10
- Debt / equity3.16 as of 2026-07-10
- Revenue growth (YoY)+96.0% as of 2026-07-10
- Revenue CAGR (3y)+64.9% SEC XBRL
- Beta1.02 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: pegtibatinase is still in pivotal Phase 3 development with manufacturing scale-up challenges that caused voluntary enrollment pause; success is uncertain","Competitive risk: other companies may develop alternative treatments for IgAN, FSGS, or homocystinuria, potentially reducing addressable market and commercial opportunity","Regulatory and reimbursement risk: orphan drug exclusivity provides protection, but actual patient adoption, insurance coverage, and pricing power may be constrained in small rare disease markets"]
Competitors & peers
- Chinook Therapeutics
- Reata Pharmaceuticals
- Aurinia Pharmaceuticals
- ChemoCentryx
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.